It seems that the hypertension ( HTN) seen by patients being treated with Ibrutinib continues to rise year on year with treatment.
At 5 years 74% of patients experienced an increase in Systolic Blood Pressure of ≥10 which is a huge number of patients. This hypertension is also often difficult to control well.
New HTN on ibrutinib was not associated with: tobacco use, obesity, chronic kidney disease or obstructive sleep apnea (p > 0.05).
"New HTN in patients on prolonged ibrutinib treatment is persistent, linear and independent of other risk factors. The increase in BP remained despite initiation of anti-HTN therapy. Additional studies are ongoing to define cardiovascular and renal complications associated with HTN in these patients"
A bit more here: meetinglibrary.asco.org/rec...